Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Precigen Inc (PGEN)

Precigen Inc (PGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 441,278
  • Shares Outstanding, K 208,150
  • Annual Sales, $ 103,870 K
  • Annual Income, $ -92,170 K
  • 60-Month Beta 2.10
  • Price/Sales 4.11
  • Price/Cash Flow N/A
  • Price/Book 7.65
Trade PGEN with:

Options Overview Details

View History
  • Implied Volatility 250.40% ( +19.11%)
  • Historical Volatility 87.17%
  • IV Percentile 85%
  • IV Rank 30.51%
  • IV High 639.46% on 07/29/22
  • IV Low 79.60% on 11/23/21
  • Put/Call Vol Ratio 0.30
  • Today's Volume 13
  • Volume Avg (30-Day) 591
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 25,729
  • Open Int (30-Day) 26,346

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate 0.09
  • Number of Estimates 2
  • High Estimate 0.32
  • Low Estimate -0.13
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +160.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.97 +2.80%
on 10/03/22
2.90 -30.34%
on 09/09/22
-0.36 (-15.13%)
since 09/02/22
3-Month
1.44 +40.28%
on 07/06/22
2.90 -30.34%
on 09/09/22
+0.61 (+43.26%)
since 07/01/22
52-Week
1.12 +80.36%
on 05/10/22
5.60 -63.93%
on 11/04/21
-3.09 (-60.47%)
since 10/01/21

Most Recent Stories

More News
Precigen Names Rutul R. Shah Chief Operating Officer

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

PGEN : 2.02 (-4.72%)
Precigen to Participate in the 2022 Wells Fargo Healthcare Conference

/PRNewswire/ -- Precigen, Inc. (NASDAQ: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

PGEN : 2.02 (-4.72%)
Precigen Completes Sale of Non-Healthcare Subsidiary Trans Ova Genetics

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

PGEN : 2.02 (-4.72%)
Precigen, Inc. (PGEN) Reports Q2 Loss, Lags Revenue Estimates

Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 18.75% and 83.41%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

PGEN : 2.02 (-4.72%)
KMDA : 4.48 (-0.67%)
Precigen Reports Second Quarter and First Half 2022 Financial Results

– Enrollment complete in Phase 1 study of PRGN-3006 UltraCAR-T® in acute myeloid leukemia (AML); enrollment ongoing in Phase 1b dose expansion study; Mayo...

PGEN : 2.02 (-4.72%)
NeoGenomics (NEO) Expected to Beat Earnings Estimates: Should You Buy?

NeoGenomics (NEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NEO : 8.71 (+1.16%)
PGEN : 2.02 (-4.72%)
Precigen to Announce Second Quarter and First Half 2022 Financial Results on August 8th

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

PGEN : 2.02 (-4.72%)
Analysts Estimate Precigen, Inc. (PGEN) to Report a Decline in Earnings: What to Look Out for

Precigen, Inc. (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PGEN : 2.02 (-4.72%)
AVEO : 8.65 (+5.10%)
Precigen, Inc. (PGEN) Upgraded to Buy: Here's What You Should Know

Precigen, Inc. (PGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PGEN : 2.02 (-4.72%)
Apellis Pharmaceuticals, Inc. (APLS) Moves 16.3% Higher: Will This Strength Last?

Apellis Pharmaceuticals, Inc. (APLS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could...

APLS : 61.06 (-10.60%)
PGEN : 2.02 (-4.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional...

See More

Key Turning Points

3rd Resistance Point 2.36
2nd Resistance Point 2.28
1st Resistance Point 2.20
Last Price 2.02
1st Support Level 2.03
2nd Support Level 1.95
3rd Support Level 1.87

See More

52-Week High 5.60
Fibonacci 61.8% 3.89
Fibonacci 50% 3.36
Fibonacci 38.2% 2.83
Last Price 2.02
52-Week Low 1.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar